MSN Labs had earlier launched a Covid treatment portfolio of Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Oseltamivir) in 75 mg capsules and also obtained a voluntary license for Baridoz (Baricitinib) last week from Eli Lilly.
